CUE Stock On Track For Best Day In History — Why Is Retail Optimistic?

• Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025. 
• The company added on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development and commercial milestone-based payments. 
• CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic.

Shares of Cue Biopharma, Inc. (CUE) is on track to record its best session to date, if gains hold, after the company announced earlier this week that it will receive $7.5 million as milestone payment from an agreement with Boehringer Ingelheim.

CUE stock is up 77% at the time of writing.

Cue- Boehringer Ingelheim Deal

Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement in April 2025  to develop and commercialize Cue Biopharma’s CUE-501 product candidate for autoimmune diseases.

Under the deal, Cue received an upfront payment of $12 million and is eligible to earn up to about $345 million in research, development and commercial milestone-based payments, as well as royalty payments on net sales.

The company now expects a $7.5 million payment in May 2026. Cue Biopharma also said on Wednesday that it is still eligible to earn up to $337.5 million more in additional research, development, and commercial milestone-based payments.

CEO Lucinda Warren said that the company is pleased with the milestone payment as it progresses its lead autoimmune asset, CUE-401, toward the clinic. In February, the company said that its preclinical data demonstrated that CUE-401 was well tolerated with no adverse events.

How Did Retail Traders React?

On Stocktwits, retail sentiment around CUE stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.

A Stocktwits user expressed optimism about the rally after a quiet period. “This is starting to get interesting,” they wrote

Another user highlighted the possibility of additional payments under the deal.

CUE stock has fallen 28% over the past 12 months. 

Read More: REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?

For updates and corrections, email newsroom[at]stocktwits[dot]com.